These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28358042)

  • 1. Spatial and molecular resolution of diffuse malignant mesothelioma heterogeneity by integrating label-free FTIR imaging, laser capture microdissection and proteomics.
    Großerueschkamp F; Bracht T; Diehl HC; Kuepper C; Ahrens M; Kallenbach-Thieltges A; Mosig A; Eisenacher M; Marcus K; Behrens T; Brüning T; Theegarten D; Sitek B; Gerwert K
    Sci Rep; 2017 Mar; 7():44829. PubMed ID: 28358042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.
    Mundt F; Johansson HJ; Forshed J; Arslan S; Metintas M; Dobra K; Lehtiö J; Hjerpe A
    Mol Cell Proteomics; 2014 Mar; 13(3):701-15. PubMed ID: 24361865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The secretome signature of malignant mesothelioma cell lines.
    Manfredi M; Martinotti S; Gosetti F; Ranzato E; Marengo E
    J Proteomics; 2016 Aug; 145():3-10. PubMed ID: 26921831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemistry of cytokeratins 7, 8, 17, 18, and 19, and GLUT-1 aids differentiation of desmoplastic malignant mesothelioma from fibrous pleuritis.
    Horiuchi T; Ogata S; Tominaga S; Hiroi S; Kawahara K; Hebisawa A; Irei I; Ito I; Kameya T; Tsujimura T; Nakano T; Nakanishi K; Kawai T
    Histol Histopathol; 2013 May; 28(5):663-70. PubMed ID: 23224745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse malignant mesothelioma and synchronous lung cancer: A clinicopathological study of 18 cases.
    Butnor KJ; Brownlee NA; Mahar A; Pavlisko EN; Sporn TA; Roggli VL
    Lung Cancer; 2016 May; 95():1-7. PubMed ID: 27040844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatial proteome profiling by immunohistochemistry-based laser capture microdissection and data-independent acquisition proteomics.
    Huang P; Kong Q; Gao W; Chu B; Li H; Mao Y; Cai Z; Xu R; Tian R
    Anal Chim Acta; 2020 Aug; 1127():140-148. PubMed ID: 32800117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Label-Free Proteomics for Quantitative Analysis of Urothelial Carcinoma and Cystitis Tissue.
    Witzke KE; Großerueschkamp F; Gerwert K; Sitek B
    Methods Mol Biol; 2021; 2228():283-292. PubMed ID: 33950498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Well-differentiated papillary mesothelioma, possibly giving rise to diffuse malignant mesothelioma: a case report.
    Washimi K; Yokose T; Amitani Y; Nakamura M; Osanai S; Noda H; Kawachi K; Takasaki H; Akaike M; Kameda Y
    Pathol Int; 2013 Apr; 63(4):220-5. PubMed ID: 23692423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Met expression and MET amplification in malignant pleural mesothelioma.
    Bois MC; Mansfield AS; Sukov WR; Jenkins SM; Moser JC; Sattler CA; Smith CY; Molina JR; Peikert T; Roden AC
    Ann Diagn Pathol; 2016 Aug; 23():1-7. PubMed ID: 27402216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
    Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
    Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
    McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
    Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic profiling of human islets collected from frozen pancreata using laser capture microdissection.
    Zhang L; Lanzoni G; Battarra M; Inverardi L; Zhang Q
    J Proteomics; 2017 Jan; 150():149-159. PubMed ID: 27620696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The advantage of laser-capture microdissection over whole tissue analysis in proteomic profiling studies.
    De Marchi T; Braakman RB; Stingl C; van Duijn MM; Smid M; Foekens JA; Luider TM; Martens JW; Umar A
    Proteomics; 2016 May; 16(10):1474-85. PubMed ID: 27030549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
    Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
    J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Label-Free LC-MS/MS Strategy for Comprehensive Proteomic Profiling of Human Islets Collected Using Laser Capture Microdissection from Frozen Pancreata.
    Zhang L; Lanzoni G; Battarra M; Inverardi L; Zhang Q
    Methods Mol Biol; 2019; 1871():253-264. PubMed ID: 30276744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
    Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
    J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatially Resolved Proteome Mapping of Laser Capture Microdissected Tissue with Automated Sample Transfer to Nanodroplets.
    Zhu Y; Dou M; Piehowski PD; Liang Y; Wang F; Chu RK; Chrisler WB; Smith JN; Schwarz KC; Shen Y; Shukla AK; Moore RJ; Smith RD; Qian WJ; Kelly RT
    Mol Cell Proteomics; 2018 Sep; 17(9):1864-1874. PubMed ID: 29941660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
    Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
    Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
    Capkova L; Koubkova L; Kodet R
    Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.